Skip to main content

Featured

A Pricey Path to Residency: Trump Administration Unveils $1M Gold Card Visa

  The Trump administration has announced the launch of a new immigration initiative dubbed the Gold Card Visa , a program that grants residency to foreign nationals willing to invest $1 million. Marketed as a fast-track entry into the United States, the visa is designed to attract wealthy investors and entrepreneurs seeking long-term opportunities in the country. Officials describe the program as a way to boost economic growth by channeling foreign capital into American businesses and infrastructure. Critics, however, argue that the policy favors the ultra-rich while sidelining skilled workers and families who lack the financial means to participate. The Gold Card Visa is expected to generate debate over the balance between economic incentives and equitable access to immigration. Supporters see it as a pragmatic move to secure investment, while opponents warn it could deepen inequality in the immigration system.
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment